20.03.2013 - Belgian UCB S.A. and US-based biologics specialist Five Prime Therapeutics have entered into a drug discovery collaboration.
The companies will screen for new targets and therapeutics in the areas of fibrosis-related inflammatory diseases and central nervous system (CNS) disorders. Under the terms of the agreement, UCB will gain exclusive access to FivePrime's library of 5.600 functionally secreted proteins and receptor proteins in up to five programmes to identify new targets and disease mechanisms.
FivePrime will receive US$16m for providing its library and screening platform, a combination of an upfront fee, technology access fees, research funding and success-based research milestone payments. UCB has an option to license exclusively rights to selected protein targets discovered by FivePrime within the collaboration. In addition, FivePrime would be eligible for potential option exercise fees and product-related milestone payments, as well as tiered royalties on global net sales on future products related to each licensed protein.
Further financial details are subject to a confidentially agreement.
23.07.2014 In the largest genomic study published on any psychiatric disorder so far, researchers have indentified 83 new locations in the human genome associated with the risk of developing schizophrenia.
15.07.2014 British specialty pharma company Prostrakan is handing over £230m for Archimedes Pharma Limited, a company that brings its lead product Pecfent and its proprietary drug delivery technology platform into the deal.
11.07.2014 Among the seven newly launched Joint Technology Initiatives (JTI) of Horizon2020 are two with deep roots in biotech: IMI is going into its second round while the newly established Bio-based Industries partnership invests in bioeconomy.